Revive Therapeutics INC.
pharmaceutical and therapeutics manufacturer
🤖
AI Overview
With $115K in lobbying spend across 11 quarterly filings, Revive Therapeutics INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2021 to 2023.
$115K
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $90K |
| 2022 | $25K |
| 2023 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •Advocating for acceleration and approval of bucillamine as a COVID-19 critical therapeutic solution. In addition, advocating for TBI, PTSD applications of other medicines in development.
- •Advocating for assistance w/Phase 3 trial for Bucillamine
- •Advocating for assistance w/Phase 3 trial for Bucillamine, educating Members of Congress, BARDA/HHS and NIH regarding Bucillamine as a repurposed drug for COVID19.
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.